-
2024-513015-27-00
5
2025-01-09
Moderately to Severely Active Ulcerative Colitis (UC)
-
2023-509069-19-00
4
2024-12-12
idiopathic pulmonary fibrosis
-
2023-505989-29-00
5
2024-11-21
Extensive stage small cell lung cancer (ES-SCLC)
-
2023-508932-68-00
4
2024-11-14
Diabetic Peripheral Neuropathic Pain
-
2024-510581-17-00
4
2024-11-05
Adult subjects with New York Heart Association (NYHA) Class III conges
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2024-510695-20-00
5
2024-10-15
Primary Biliary Cholangitis (PBC)
-
2024-515936-62-00
9
2024-10-10
Patients with advanced or metastatic gastrointestinal (GI) tumors.
-
2024-511212-24-00
9
2024-10-07
Advanced solid tumors
-
2023-510279-80-00
4
2024-09-25
Prurigo nodularis
-
2024-511195-33-00
3
2024-09-23
Gastrointestinal tract, biliary tract, or pancreatic cancers with homo
-
2022-502605-15-00
4
2024-09-16
Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
-
2023-508219-21-00
5
2024-09-12
BTC - Biliary Tract Cancer
-
2023-506769-67-00
4
2024-09-04
Moderate to Severely Active Ulcerative Colitis
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2024-511260-84-00
4
2024-09-03
Atopic Dermatitis
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-505423-31-00
5
2024-08-08
advanced or metastatic gastric adenocarcinoma, gastroesophageal juncti
-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-507204-31-00
5
2024-07-26
Hidradenitis Suppurativa
-
2023-503923-24-00
5
2024-07-22
Sjögren’s Syndrome With Moderate-toSevere Symptom State
-
2023-506334-75-00
5
2024-07-12
Pulmonary Arterial Hypertension
-
2023-506054-20-00
5
2024-06-05
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
-
2023-508426-10-00
3
2024-06-03
Relapsed/Refractory Multiple Myeloma